SEOVF - Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
(TheNewswire)
LONDON, ONTARIO - TheNewswire – December 16, 2021 –Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stageregenerative medicine and cell therapy therapeutics company focused ondeveloping a potential ‘functional cure’ for type 1 diabetes (T1D)and other chronic diseases, is pleased to announce that Dr. Piotr Witkowski, principalinvestigator of Sernova’s Phase I/II clinical trial will presentupdated interim results from the ongoing safety, tolerability andefficacy study of Sernova’s Cell Pouch™ in a poster session at theAmerican Society of Transplant Surgeons (ASTS) 22nd Annual “State ofthe Art” Winter Symposium on January 13, 2022.
Dr. Witkowski’s presentation entitled, A Modified Approach for Improved IsletAllotransplantation into the Pre-vascularized Sernova Cell Pouch™device-preliminary results of the phase I and II clinical study atUniversity of Chicago, will be presented to more than 600 transplant professionals as part ofAbstract Session A, starting at 5:30 PM. Further details on theprogram and registration can be found on the ASTS Winter Symposiumwebsite: https://asts.org/events-meetings/winter-symposium
The ASTS Winter Symposium is the same conference where,in January 2021, Dr. Witkowski presented positive preliminary safetyand efficacy data indicating that Sernova’s Cell Pouch™transplanted with insulin producing cells in patients with type 1diabetes showed persistent islet function and clinically meaningfulimprovement in measures of glucose control.
ABOUT ASTS AND THE 22nd ANNUALSTATE OF THE ART WINTER SYMPOSIUM
The American Society of Transplant Surgeons representsapproximately 1,900 professionals, regulatory authorities andpharmaceutical representatives dedicated to excellence intransplantation surgery. ASTS advances the art and science oftransplant surgery through patient care, research, education, andadvocacy.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeuticsolutions using a medical device (Cell Pouch) and immune protectedtherapeutic cells / tissues (i.e. human donor cells, corrected humancells and stem cell-derived cells) to improve the treatment andquality of life of people with chronic metabolic diseases such asinsulin-dependent diabetes, blood disorders including hemophilia, andother diseases treated through cellular production of proteins orhormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has beenshown to provide long-term safety and efficacy in small and largeanimal models of diabetes and has been proven to provide abiologically compatible environment for insulin-producing cells inhumans in a Canadian first-in-human study. Sernova is currentlyconducting a Phase I/II study at the University of Chicago. Positiveinitial results have been presented at several internationalscientific conferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Corey Davis, Ph.D.
LifeScience Advisors, LLC
Tel: 212-915-2577
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events and are based on information currentlyavailable to management on the date such statements were made. Manyfactors could cause Sernova’s actual results, performances orachievements to not be as anticipated, estimated or intended or todiffer materially from those expressed or implied by theforward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.